DistillerSR Launches the Industry's Most Advanced GenAI Capabilities for Extracting Scientific Literature Evidence
8.4.2026 16:00:00 CEST | ACCESS Newswire | Press release
DistillerSR's Smart Evidence Extraction Now Fully Automates Text and Table Data at Scale
OTTAWA, ON / ACCESS Newswire / April 8, 2026 / DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced new fully automated capabilities for its Smart Evidence Extraction (SEE) module. SEE uses purpose-built GenAI to automate end‑to‑end workflows for extracting evidence from scientific literature at scale, while maintaining full auditability and human governance over AI‑generated outputs.
As the volume of published research continues to grow exponentially, research teams in the pharmaceutical and medical device industries face increasing pressure to monitor evidence with speed and precision. SEE enables research professionals to accurately find, suggest, explain, extract, and link the supporting evidence within the reference in a human-in-the-loop and fully automated workflow.
"The latest version of SEE is designed to move research teams from reactive to proactive evidence strategy," said Peter O'Blenis, CEO of DistillerSR. "By automating the most time-consuming and error-prone aspects of data extraction, we are helping our customers deliver life-saving research to markets and patients more cost effectively, and with greater transparency and confidence."
New SEE functionality includes:
Full Form Automation: SEE now completes and submits entire extraction forms automatically, replicating a human reviewer's workflow to significantly reduce manual labor.
Enhanced Accuracy & Scope: The latest version of SEE demonstrated an 8.3 percentage point overall improvement on the standardized literature question-answering (LitQA) benchmark compared to its previous version, which is well above comparative benchmarks.
Contextual Processing: Simplified prompting allows SEE to process all questions in a form simultaneously, allowing it to understand the full context of the extraction form and the relationships between variables for improved accuracy and consistency.
Explainable AI: To facilitate regulatory compliance and trust, SEE provides plain-language explanations for every suggested answer, including full auditability of AI-extracted data.
Real-Time Monitoring: An AI Dashboard enables teams to track and manage usage, while monitoring AI costs in real time.
Adherence to AI Product Standards: Extracted data is fully hosted within DistillerSR's secure platform with zero customer data used for model training. The company has adopted the NIST AI Risk Management Framework to govern the design, deployment, testing, and validation of DistillerSR AI capabilities.
The latest iteration of SEE marks a significant milestone in DistillerSR's three-year Eureka-ITEA research consortium, the world's largest international research and development network representing 45 countries. The six-country research consortium is led by DistillerSR, and includes Philips Medical Systems, University of Leiden Medical Center, Bosonit,Dataseen BV, Össur, Adelphi Group, Biotronik, and DrugBank. Consortium members are working together to build AI-enabled workflows for research organizations that integrate Agentic AI, enrich underlying evidence with standard clinical and ontologies, and support the EU's healthcare data spaces initiatives.
DistillerSR is trusted by global research organizations, including more than 80% of the largest pharmaceutical and medical device companies, contract research organizations, governments, NGOs, and academic institutions.
About DistillerSR
For more information, visit www.distillersr.com.
DistillerSR Inc. Media Contact:
Vivian MacAdden
vivian.macadden@distillersr.com
SOURCE: DistillerSR Inc.
View the original press release on ACCESS Newswire
DistillerSR Inc.

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GTDC Highlights Distributors' Vital Role in Scaling AI Adoption and Digital Transformation15.4.2026 15:00:00 CEST | Press release
Industry leaders stress that digital platforms, support, and collaboration are essential to boost sales, engage channels, and respond to shifts in global trade, workforce shortages, and the rise of robotics and AI. Technology distribution is evolving as these "AI-first" partners emerge, developing and deploying original AI solutions that define a new era of applied AI. IT distributors help speed up cloud, AI, and emerging tech adoption by investing in advanced systems and services for vendors and solution providers. NOORDWIJK, NL / ACCESS Newswire / April 15, 2026 / IT distributors have become a driving force behind the sales and adoption of AI, advanced cloud and cybersecurity solutions and other next‑generation technologies based on research and discussions at this week's GTDC Summit EMEA conference. The quickly evolving digital landscape was a central theme of the annual channel executive event, hosted by the Global Technology Distribution Council (GTDC), the world's largest consort
GTDC Highlights Distributors' Vital Role in Scaling AI Adoption and Digital Transformation15.4.2026 15:00:00 CEST | Press release
Industry leaders stress that digital platforms, support, and collaboration are essential to boost sales, engage channels, and respond to shifts in global trade, workforce shortages, and the rise of robotics and AI. Technology distribution is evolving as these "AI-first" partners emerge, developing and deploying original AI solutions that define a new era of applied AI. IT distributors help speed up cloud, AI, and emerging tech adoption by investing in advanced systems and services for vendors and solution providers. NOORDWIJK, NL / ACCESS Newswire / April 15, 2026 / IT distributors have become a driving force behind the sales and adoption of AI, advanced cloud and cybersecurity solutions and other next‑generation technologies based on research and discussions at this week's GTDC Summit EMEA conference. The quickly evolving digital landscape was a central theme of the annual channel executive event, hosted by the Global Technology Distribution Council (GTDC), the world's largest consort
GoodData Kicks Off 2026 with MCP Server Launch and Major Enterprise Wins15.4.2026 12:00:00 CEST | Press release
Financial services wins and three platform launches signal accelerating enterprise demand for agentic analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q1 2026 results driven by the launch of its MCP Server for agentic analytics, significant new contracts in global financial services, and continued expansion into new markets. The quarter built on a record-breaking 2025, reinforcing GoodData's position as the platform enterprises trust to move AI from pilot to production. Continued growth across enterprise and financial services GoodData's commercial momentum remained strong throughout Q1, with notable wins across the enterprise and financial sectors. The company secured a new three-year contract with one of the world's largest asset managers, and a key long-term customer in global payments renewed for three years while expanding its enterprise license. "Our Q1 results demonstrate that t
GoodData Kicks Off 2026 with MCP Server Launch and Major Enterprise Wins15.4.2026 12:00:00 CEST | Press release
Financial services wins and three platform launches signal accelerating enterprise demand for agentic analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q1 2026 results driven by the launch of its MCP Server for agentic analytics, significant new contracts in global financial services, and continued expansion into new markets. The quarter built on a record-breaking 2025, reinforcing GoodData's position as the platform enterprises trust to move AI from pilot to production. Continued growth across enterprise and financial services GoodData's commercial momentum remained strong throughout Q1, with notable wins across the enterprise and financial sectors. The company secured a new three-year contract with one of the world's largest asset managers, and a key long-term customer in global payments renewed for three years while expanding its enterprise license. "Our Q1 results demonstrate that t
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom